SCHEMBL17696341

SCHEMBL17696341

C=CC(=O)OCCOCCOC(=O)CCC(=O)OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 8/20 0.66
ALDH1A1 P00352 6/20 0.66
TP53 P04637 3/20 0.66
HIF1A Q16665 3/20 0.66
HSD17B10 Q99714 2/20 0.66
THRB P10828 2/20 0.50
HPGD P15428 1/20 0.46
CYP3A4 P08684 2/20 0.46
LMNA P02545 3/20 0.40
ADRA2A P08913 1/20 0.37
ADRA1A P35348 1/20 0.37
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
BLM P54132 1/20 0.36
DGKA P23743 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822549 1.00 TSHR (0.66) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL2611999 0.95 TSHR (0.55) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL17696338 0.91 TSHR (0.68) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL28959488 0.91 TSHR (0.79) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL10080348 0.88 TSHR (0.62) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL28181728 0.88 TSHR (0.57) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL242130 0.85 TSHR (0.76) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL9280497 0.85 TSHR (0.76) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL9141648 0.85 TSHR (0.76) TSHRALDH1A1TP53HIF1AHSD17B10
SCHEMBL17119709 0.85 TSHR (0.67) TSHRALDH1A1TP53HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212136-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT FUJIFILM CORPORATION (JP) 2023-07-06 US disclosed
US-20170349828-A1 POLYMERIZABLE COMPOSITION, FILM, AND HALF MIRROR FOR DISPLAYING PROJECTION IMAGE FUJIFILM CORPORATION (JP) 2017-12-07 US disclosed
US-20160108315-A1 OPTICALLY ANISOTROPIC LAYER, METHOD FOR PRODUCING THE OPTICALLY ANISOTROPIC LAYER, A LAMINATE, POLARIZING PLATE, DISPLAY DEVICE, LIQUID CRYSTAL COMPOUND, METHOD FOR PRODUCING THE LIQUID CRYSTAL COMPOUND, AND CARBOXYLIC ACID COMPOUND FUJIFILM CORPORATION (JP) 2016-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212136-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT TERB1, RER1, LARP1 TSHR 3138/4885ALDH1A1 228/4885TP53 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.